Skip to main content
SpringerLink
Log in

Molecular Pathology of Oligodendroglial Tumors

  • Chapter
Gliomas

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 171))

The term oligodendroglioma was created by Bailey, Cushing, and Bucy based on the observation that these tumors share morphological similarities with oligodendrocytes (Bailey and Cushing 1926; Bailey and Bucy 1929). However, a convincing link between oligodendrocytes and oligodendrogliomas still needs to be shown. Oligoastrocytomas or mixed gliomas are histologically defined by the presence of oligodendroglial and astrocytic components. According to the WHO classification of brain tumors, oligodendroglial tumors are separated into oligodendrogliomas WHO grade II (OII), anaplastic oligodendrogliomas WHO grade III (OIII), oligoastrocytomas WHO grade II (OAII), anaplastic oligoastrocytomas WHO grade III (OAIII), and glioblastomas with oli-godendroglioma component WHO grade IV (GBMo) (Louis et al. 2007).The perception of oligodendroglial tumors has changed in recent years. The diagnosis of oligodendroglioma or oligoastrocytomas is made much more frequently than 10 years ago. Treatment modalities have been advanced and novel concepts regarding the origin of oligodendroglial tumors have been developed. This review focuses on recent developments with impact on the diagnosis and understanding of molecular mechanisms in oli-godendroglial tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aguirre-Cruz L, Mokhtari K, Hoang-Xuan K, Marie Y, Criniere E, Taillibert S, Lopes M, Delattre JY, Sanson M (2004) Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors. J Neurooncol 67:265–271

    PubMed  Google Scholar 

  • Alonso ME, Bello MJ, Arjona D, Martinez-Glez V, de Campos JM, Isla A, Kusak E, Vaquero J, Gutierrez M, Sarasa JL, Rey JA (2005) Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendroglio-mas. Am J Clin Pathol 123:900–906

    PubMed  CAS  Google Scholar 

  • Anguelova E, Beuvon F, Leonard N, Chaverot N, Varlet P, Couraud PO, Daumas-Duport C, Cazaubon S (2005) Functional endothelin ET B receptors are selectively expressed in human oligodendrogliomas. Brain Res Mol Brain Res 137:77–88

    PubMed  CAS  Google Scholar 

  • Azzarelli B, Miravalle L, Vidal R (2004) Immuno-localization of the oligodendrocyte transcription factor 1 (Olig1) in brain tumors. J Neuropathol Exp Neurol 63:170–179

    PubMed  CAS  Google Scholar 

  • Bailey P, Bucy P (1929) Oligodendrogliomas of the brain. J Pathol Bacteriol 32:735–754

    Google Scholar 

  • Bailey P, Cushing H (1926) A Classification of Tumors of the Glioma Group on a Histogenetic basis with a Correlation Study of Prognosis. Lippincott, Philadelphia

    Google Scholar 

  • Balls J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008 Dec;116(6):597-602. Epub 2008 Nov 5

    Google Scholar 

  • Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, Brawanski A, Bogdahn U, Beier CP (2008) CD133 expression and cancer stem cells predict prognosis in high-grade oligoden-droglial tumors. Brain Pathol 18:370–377

    PubMed  Google Scholar 

  • Bello MJ, Leone PE, Nebreda P, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Garcia-Miguel P, Queizan A, Hernandez-Moneo JL, et al. (1995a) Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 83:160–164

    CAS  Google Scholar 

  • Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Pestana A, Rey JA (1995b) Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oli-godendroglial tumors. Int J Cancer 64:207–210

    CAS  Google Scholar 

  • Bello MJ, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Saez-Castresana J, Pestana A, Rey JA (1994) Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oli-godendroglial tumors. Int J Cancer 57:172–175

    PubMed  CAS  Google Scholar 

  • Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD (1999) Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155:375–386

    PubMed  CAS  Google Scholar 

  • Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Chio A, Mauro A, Schiffer D (2000) CDKN2A/ p16 inactivation in the prognosis of oligodendro-gliomas. Int J Cancer 88:554–557

    PubMed  CAS  Google Scholar 

  • Boulay JL, Miserez AR, Zweifel C, Sivasankaran B, Kana V, Ghaffari A, Luyken C, Sabel M, Zerrouqi A, Wasner M, Van Meir E, Tolnay M, Reifenberger G, Merlo A (2007) Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS ONE 2:e576

    PubMed  Google Scholar 

  • Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M (2006) Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolo-mide in anaplastic and recurrent oligodendrogli-oma: a prospective GICNO study. J Clin Oncol 24:4746–4753

    PubMed  CAS  Google Scholar 

  • Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, Huntley BK, Goldthwaite PT, Jenkins RB, Feuerstein BG (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraff in-embedded sections. Mod Pathol 14:842–853

    CAS  Google Scholar 

  • Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714

    PubMed  CAS  Google Scholar 

  • Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C, Jr., et al. (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013–2021

    CAS  Google Scholar 

  • Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemother-apeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479

    PubMed  CAS  Google Scholar 

  • Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G (2003) Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61:267–273

    PubMed  Google Scholar 

  • Chin HW, Hazel JJ, Kim TH, Webster JH (1980) Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas. Cancer 45:1458–1466

    CAS  Google Scholar 

  • Coleman KE, Brat DJ, Cotsonis GA, Lawson D, Cohen C (2006) Proliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significance. Appl Immunohistochem Mol Morphol 14:109–114

    PubMed  CAS  Google Scholar 

  • Cooke HJ (2004) Silence of the centromeres—not. Trends Biotechnol 22:319–321

    PubMed  CAS  Google Scholar 

  • Coons S W, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1393

    PubMed  CAS  Google Scholar 

  • Dai C, Lyustikman Y, Shih A, Hu X, Fuller GN, Rosenblum M, Holland EC (2005) The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Neoplasia 7:397–406

    PubMed  CAS  Google Scholar 

  • Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg 88:1–10

    PubMed  CAS  Google Scholar 

  • de la Monte SM (1989) Uniform lineage of oli-godendrogliomas. Am J Pathol 135:529–540

    PubMed  Google Scholar 

  • Dehghani F, Schachenmar W, Laun A, Korf HW (1998) Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol (Berl) 95:493–504

    CAS  Google Scholar 

  • Diedrich U, Soja S, Behnke J, Zoll B (1991) Amplification of the c-erbB oncogene is associated with malignancy in primary tumours of neuroepi-thelial tissue. J Neurol 238:221–224

    PubMed  CAS  Google Scholar 

  • Dirks PB (2008) Brain tumor stem cells: bringing order to the chaos of brain cancer. J Clin Oncol 26:2916–2924

    PubMed  Google Scholar 

  • Dong ZQ, Pang JC, Tong CY, Zhou LF, Ng HK (2002) Clonality of oligoastrocytomas. Hum Pathol 33:528–535

    PubMed  Google Scholar 

  • Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A (1998) PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16:2259–2264

    PubMed  CAS  Google Scholar 

  • Fan X, Salford LG, Widegren B (2007) Glioma stem cells: Evidence and limitation. Semin Cancer Biol 17:214–218

    PubMed  CAS  Google Scholar 

  • Ferraresi S, Servello D, De Lorenzi L, Allegranza A (1989) Familial frontal lobe oligodendroglioma. Case report. J Neurosurg Sci 33:317–318

    CAS  Google Scholar 

  • Fuller GN, Hess KR, Rhee CH, Yung WK, Sawaya RA, Bruner JM, Zhang W (2002) Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol 12:108–116

    PubMed  CAS  Google Scholar 

  • Gadji M, Tsanaclis A-M, Fortin D, Drouin R (2008) Aneuploidy and chromosomal instability in glio-mas. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; Apr 12–16, 2008; Philadelphia (PA): AACR; 2008. Abstract nr 4331

    Google Scholar 

  • Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30:567–573

    PubMed  CAS  Google Scholar 

  • Geisbrecht B V, Gould SJ (1999) The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem 274:30527–30533

    PubMed  CAS  Google Scholar 

  • Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K (2008) Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18:360–369

    PubMed  Google Scholar 

  • Giannini C, Scheithauer B W, Weaver AL, Burger PC, Kros JM, Mork S, Graeber MB, Bauserman S, Buckner JC, Burton J, Riepe R, Tazelaar HD, Nascimento AG, Crotty T, Keeney GL, Pernicone P, Altermatt H (2001) Oligodendrogliomas: repro-ducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60:248–262

    PubMed  CAS  Google Scholar 

  • Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF (1998) The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 49:436–440

    PubMed  CAS  Google Scholar 

  • Giordana MT, Mauro A, Soffietti R, Leone M (1981) Association between multiple sclerosis and oligoden-droglioma. Case report. Ital J Neurol Sci 2:403–409

    CAS  Google Scholar 

  • Greenfield JG, Graham DI, Lantos PL (2002) Greenfield's neuropathology. Arnold, London/ New York

    Google Scholar 

  • Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD, Murphy KM (2006) Identification of der(1;19)(q10;p10) in Five Oligodendrogliomas Suggests Mechanism of Concurrent 1p and 19q Loss. J Neuropathol Exp Neurol 65:988–994

    PubMed  Google Scholar 

  • Hart MN, Petito CK, Earle KM (1974) Mixed glio-mas. Cancer 33:134–140

    PubMed  CAS  Google Scholar 

  • Hartmann C, Johnk L, Kitange G, Wu Y, Ashworth LK, Jenkins RB, Louis DN (2002) Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res 62:4100–4108

    PubMed  CAS  Google Scholar 

  • Hartmann C, Mueller W, Lass U, Kamel-Reid S, von Deimling A (2005) Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 64:10–14

    PubMed  CAS  Google Scholar 

  • Hartmann C, Mueller W, Lass U, Stockhammer F, von Eckardstein K, Veelken J, Jeuken J, Wick W, von Deimling A (2003) No preferential loss of paternal 19q alleles in oligodendroglial tumors. Ann Neurol 54:256–258

    PubMed  CAS  Google Scholar 

  • Hartmann C, Mueller W, von Deimling A (2004) Pathology and molecular genetics of oligoden-droglial tumors. J Mol Med 82:638–655

    PubMed  CAS  Google Scholar 

  • He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P, Capelle L, Delattre JY, Poirier J, Hoang-Xuan K (2001) Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 60:863–871

    PubMed  CAS  Google Scholar 

  • Heegaard S, Sommer HM, Broholm H, Broendstrup O (1995) Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 76:1809–1813

    PubMed  CAS  Google Scholar 

  • Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    PubMed  CAS  Google Scholar 

  • Herbarth B, Meissner H, Westphal M, Wegner M (1998) Absence of polyomavirus JC in glial brain tumors and glioma-derived cell lines. Glia 22:415–420

    PubMed  CAS  Google Scholar 

  • Hoang-Xuan K, Aguirre-Cruz L, Mokhtari K, Marie Y, Sanson M (2002) OLIG-1 and 2 gene expression and oligodendroglial tumours. Neuropathol Appl Neurobiol 28:89–94

    PubMed  CAS  Google Scholar 

  • Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Criniere E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broet P, Sanson M, Delattre JY (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133–3138

    PubMed  CAS  Google Scholar 

  • Hoang-Xuan K, He J, Huguet S, Mokhtari K, Marie Y, Kujas M, Leuraud P, Capelle L, Delattre J Y, Poirier J, Broet P, Sanson M (2001) Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 57:1278–1281

    PubMed  CAS  Google Scholar 

  • Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S, Ohgaki H (2006) Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 65:846–854

    PubMed  CAS  Google Scholar 

  • Hong C, Bollen AW, Costello JF (2003) The contribution of genetic and epigenetic mechanisms to gene silencing in oligodendrogliomas. Cancer Res 63:7600–7605

    PubMed  CAS  Google Scholar 

  • Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, Thillet J, Delattre JY, Hoang-Xuan K, Sanson M (2006) Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106:2218–2223

    PubMed  CAS  Google Scholar 

  • Huang CI, Chiou WH, Ho DM (1987) Oligodendro-glioma occurring after radiation therapy for pituitary adenoma. J Neurol Neurosurg Psychiatry 50:1619–1624

    PubMed  CAS  Google Scholar 

  • Huang H, Reis R, Yonekawa Y, Lopes JM, Kleihues P, Ohgaki H (1999) Identification in human brain tumors of DNA sequences specific for SV40 large T antigen. Brain Pathol 9:33–42

    PubMed  CAS  Google Scholar 

  • Husemann K, Wolter M, Buschges R, Bostrom J, Sabel M, Reifenberger G (1999) Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 58:1041–1050

    PubMed  CAS  Google Scholar 

  • Ichimura K, Vogazianou A P, Liu L, Pearson DM, Backlund LM, Plant K, Baird K, Langford CF, Gregory SG, Collins VP (2008) 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 27:2097–2108

    PubMed  CAS  Google Scholar 

  • Idbaih A, Marie Y, Pierron G, Brennetot C, Hoang-Xuan K, Kujas M, Mokhtari K, Sanson M, Lejeune J, Aurias A, Delattre O, Delattre JY (2005) Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58:483–487

    PubMed  CAS  Google Scholar 

  • Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN (2001) Molecular subtypes of anaplastic oligodendrog-lioma: implications for patient management at diagnosis. Clin Cancer Res 7:839–845

    PubMed  CAS  Google Scholar 

  • Ironside JW, Moss TH, Louis DN, Lowe JS, Well RO (2002) Diagnostic Pathology of Nervous System Tumours. Churchill Livingstone, London

    Google Scholar 

  • Jaskolsky D, Zawirski M, Papierz W, Kotwica Z (1987) Mixed gliomas. Their clinical course and results of surgery. Zentralbl Neurochir 48:120–123

    CAS  Google Scholar 

  • Jenkins R, Blair H, Flynn H, Passe S, Law M, Ballman K, Giannini C, Buckner JC (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q in human oligodendrogliomas. In: 16th Biennial International Brain Tumor Research and Therapy Meeting, Silverado Resort ans Spa, Napa Valley, CA

    Google Scholar 

  • Jennings GT, Minard KI, McAlister-Henn L (1997) Expression and mutagenesis of mammalian cytosolic NADP+-speciWc isocitrate dehydroge-nase. Biochemistry 36:13743–13747

    PubMed  CAS  Google Scholar 

  • Jeuken J W, Nelen MR, Vermeer H, van Staveren WC, Kremer H, van Overbeeke JJ, Boerman RH (2000) PTEN mutation analysis in two genetic subtypes of high-grade oligodendroglial tumors. PTEN is only occasionally mutated in one of the two genetic subtypes. Cancer Genet Cytogenet 119:42–47

    CAS  Google Scholar 

  • Jeuken J W, Sprenger SH, Wesseling P, Macville M V, von Deimling A, Teepen HL, van Overbeeke JJ, Boerman RH (1999) Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol 58:606–612

    PubMed  CAS  Google Scholar 

  • Kashima T, Tiu SN, Merrill JE, Vinters HV, Dawson G, Campagnoni AT (1993) Expression of oligodendrocyte-associated genes in cell lines derived from human gliomas and neuroblastomas. Cancer Res 53:170–175

    PubMed  CAS  Google Scholar 

  • Kennedy PG, Watkins BA, Thomas DG, Noble MD (1987) Antigenic expression by cells derived from human gliomas does not correlate with morphological classification. Neuropathol Appl Neurobiol 13:327–347

    PubMed  CAS  Google Scholar 

  • Kim L, Hochberg FH, Thornton A F, Harsh GRt, Patel H, Finkelstein D, Louis DN (1996) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85:602–607

    PubMed  CAS  Google Scholar 

  • Kim S, Dougherty ER, Shmulevich L, Hess KR, Hamilton SR, Trent JM, Fuller GN, Zhang W (2002) Identification of combination gene sets for glioma classification. Mol Cancer Ther 1:1229–1236

    PubMed  CAS  Google Scholar 

  • Kim SY, Lee SM, Tak JK et al (2007) Regulation of singlet oxygen-induced apoptosis by cytosolic NADP+-dependent isocitrate dehydrogenase. Mol Cell Biochem 302:27–34

    PubMed  CAS  Google Scholar 

  • Kitange G, Misra A, Law M, Passe S, Kollmeyer TM, Maurer M, Ballman K, Feuerstein BG, Jenkins RB (2005) Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer 42:68–77

    PubMed  CAS  Google Scholar 

  • Kleihues P, Zulch KJ, Matsumoto S, Radke U (1970) Morphology of malignant gliomas induced in rabbits by systemic application of N-methyl-N-nitrosourea. Z Neurol 198:65–78

    PubMed  CAS  Google Scholar 

  • Kouwenhoven MC, Kros JM, French PJ, Biemond-Ter Stege EM, Graveland WJ, Taphoorn MJ, Brandes AA, van den Bent MJ (2006) 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42:2499–2503

    PubMed  CAS  Google Scholar 

  • Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, von Deimling A (1995) Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54:91–95

    PubMed  CAS  Google Scholar 

  • Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Reifenberger G, Schlegel U (2001) Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol (Berl) 101:311–320

    CAS  Google Scholar 

  • Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach J, Heese O, Reifenberger G, Weller M, Schackert G, Network TGG (2007) Long-term survival with glioblast-oma multiforme. Brain 130:2596–2606

    PubMed  Google Scholar 

  • Kros JM, Lie ST, Stefanko SZ (1994) Familial occurrence of polymorphous oligodendroglioma. Neurosurgery 34:732–736; discussion 736

    PubMed  CAS  Google Scholar 

  • Kros JM, van Run PR, Alers JC, Beverloo HB, van den Bent MJ, Avezaat CJ, van Dekken H (1999) Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH). J Pathol 188:282–288

    PubMed  CAS  Google Scholar 

  • Kunitz A, Wolter M, van den Boom J, Felsberg J, Tews B, Hahn M, Benner A, Sabel M, Lichter P, Reifenberger G, von Deimling A, Hartmann C (2007) DNA hypermethylation and Aberrant Expression of the EMP3 Gene at 19q13.3 in Human Gliomas. Brain Pathol 17:363–370

    PubMed  CAS  Google Scholar 

  • Landry C F, Verity MA, Cherman L, Kashima T, Black K, Yates A, Campagnoni AT (1997) Expression of oligodendrocytic mRNAs in glial tumors: changes associated with tumor grade and extent of neo-plastic infiltration. Cancer Res 57:4098–4104

    PubMed  CAS  Google Scholar 

  • Lebrun C, Fontaine D, Ramaioli A, Vandenbos F, Chanalet S, Lonjon M, Michiels J F, Bourg V, Paquis P, Chatel M, Frenay M (2004) Long-term outcome of oligodendrogliomas. Neurology 62:1783–1787

    PubMed  CAS  Google Scholar 

  • Lee YY, Van Tassel P (1989) Intracranial oligoden-drogliomas: imaging findings in 35 untreated cases. AJR Am J Roentgenol 152:361–369

    PubMed  CAS  Google Scholar 

  • Lee SM, Koh HJ, Park DC et al (2002) Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med 32:1185–1196

    PubMed  CAS  Google Scholar 

  • Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T (2006) Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106:1759–1765

    PubMed  CAS  Google Scholar 

  • Li KK, Pang JC, Chung NY, Ng YL, Chan NH, Zhou L, Poon WS, Ng HK (2007) EMP3 overex-pression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q. Int J Cancer 120:947–950

    PubMed  CAS  Google Scholar 

  • Ligon KL, Alberta JA, Kho AT, Weiss J, Kwaan MR, Nutt CL, Louis DN, Stiles CD, Rowitch DH (2004) The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse glio-mas. J Neuropathol Exp Neurol 63:499–509

    PubMed  CAS  Google Scholar 

  • Louis D, Ohgaki H, Wiestler O, Cavenee W (eds) (2007) World Health Organization Classification of Tumours of the Central Nervous System. IARC, Lyon

    Google Scholar 

  • Lu QR, Park JK, Noll E, Chan JA, Alberta J, Yuk D, Alzamora MG, Louis DN, Stiles CD, Rowitch DH, Black PM (2001) Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci USA 98:10851–10856

    PubMed  CAS  Google Scholar 

  • Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW (1986) A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neurol 19:15–21

    PubMed  CAS  Google Scholar 

  • Maegawa S, Yoshioka H, Itaba N, Kubota N, Nishihara S, Shirayoshi Y, Nanba E, Oshimura M (2001) Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Mol Carcinog 31:1–9

    PubMed  CAS  Google Scholar 

  • Magnani I, Moroni R F, Roversi G, Beghini A, Pfundt R, Schoenmakers E F, Larizza L (2005) Identification of oligodendroglioma specific chromosomal copy number changes in the glioblastoma MI-4 cell line by array-CGH and FISH analyses. Cancer Genet Cytogenet 161:140–145

    PubMed  CAS  Google Scholar 

  • Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl A P, Louis DN, Schramm J, Wiestler OD, von Deimling A (1997) Molecular genetic evidence for subtypes of oli-goastrocytomas. J Neuropathol Exp Neurol 56:1098–1104

    PubMed  CAS  Google Scholar 

  • Marie Y, Sanson M, Mokhtari K, Leuraud P, Kujas M, Delattre J Y, Poirier J, Zalc B, Hoang-Xuan K (2001) OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 358:298–300

    PubMed  CAS  Google Scholar 

  • McDonald JM, See SJ, Tremont I W, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, Aaron J, Tipnis U, Zhang W, Hess K, Aldape K (2005) The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104:1468–1477

    PubMed  CAS  Google Scholar 

  • McLendon RE, Herndon JE, 2nd, West B, Reardon D, Wiltshire R, Rasheed BK, Quinn J, Friedman HS, Friedman AH, Bigner DD (2005) Survival analysis of presumptive prognostic markers among oli-godendrogliomas. Cancer 104:1693–1699

    PubMed  CAS  Google Scholar 

  • Miller CR, Dunham CP, Scheithauer BW, Perry A (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24:5419–5426

    PubMed  Google Scholar 

  • Mokhtari K, Paris S, Aguirre-Cruz L, Privat N, Criniere E, Marie Y, Hauw JJ, Kujas M, Rowitch D, Hoang-Xuan K, Delattre JY, Sanson M (2005) Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuro-pathol Appl Neurobiol 31:62–69

    CAS  Google Scholar 

  • Mork SJ, Halvorsen TB, Lindegaard K F, Eide GE (1986) Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 45:65–78

    CAS  Google Scholar 

  • Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161:313–319

    PubMed  CAS  Google Scholar 

  • Mukasa A, Ueki K, Ge X, Ishikawa S, Ide T, Fujimaki T, Nishikawa R, Asai A, Kirino T, Aburatani H (2004) Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol 14:34–42

    PubMed  CAS  Google Scholar 

  • Mukasa A, Ueki K, Matsumoto S, Tsutsumi S, Nishikawa R, Fujimaki T, Asai A, Kirino T, Aburatani H (2002) Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 21:3961–3968

    PubMed  CAS  Google Scholar 

  • Nutt CL, Betensky RsA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO (2005) YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 11:2258–2264

    PubMed  CAS  Google Scholar 

  • Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602–1607

    PubMed  CAS  Google Scholar 

  • Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb E W, Kleihues P (1991) p53 mutations in nonastrocytic human brain tumors. Cancer Res 51:6202–6205

    PubMed  CAS  Google Scholar 

  • Ohnishi A, Sawa H, Tsuda M, Sawamura Y, Itoh T, Iwasaki Y, Nagashima K (2003) Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas. J Neuropathol Exp Neurol 62:1052–1059

    PubMed  CAS  Google Scholar 

  • Okamoto H, Li J, Glasker S, Vortmeyer AO, Jaffe H, Robison RA, Bogler O, Mikkelsen T, Lubensky IA, Oldfield EH, Zhuang Z (2007) Proteomic Comparison of Oligodendrogliomas with and without 1pLOH. Cancer Biol Ther 6

    Google Scholar 

  • Olson JD, Riedel E, DeAngelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442–1448

    PubMed  CAS  Google Scholar 

  • Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812

    PubMed  CAS  Google Scholar 

  • Perentes E, Rubinstein LJ (1987) Recent applications of immunoperoxidase histochemistry in human neuro-oncology. An update. Arch Pathol Lab Med 111:796–812

    CAS  Google Scholar 

  • Perez-Diaz C, Cabello A, Lobato RD, Rivas JJ, Cabrera A (1985) Oligodendrogliomas arising in the scar of a brain contusion. Report of two surgically verified cases. Surg Neurol 24:581–586

    CAS  Google Scholar 

  • Pohl U, Cairncross JG, Louis DN (1999) Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oli-godendrogliomas. Brain Pathol 9:639–643

    PubMed  CAS  Google Scholar 

  • Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP (2003) Anaplastic oli-godendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65:259–266

    PubMed  Google Scholar 

  • Qu M, Olofsson T, Sigurdardottir S, You C, Kalimo H, Nister M, Smits A, Ren ZP (2007) Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol (Berl) 113:129–136

    CAS  Google Scholar 

  • RaV MC, Miller RH, Noble M (1983) A glial progenitor cell that develops in vitro into an astro-cyte or an oligodendrocyte depending on culture medium. Nature 303:390–396

    Google Scholar 

  • Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126

    PubMed  CAS  Google Scholar 

  • Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP (1996) Epidermal growth factor receptor expression in oligoden-droglial tumors. Am J Pathol 149:29–35

    PubMed  CAS  Google Scholar 

  • Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190

    PubMed  CAS  Google Scholar 

  • Riemenschneider MJ, Reifenberger J, Reifenberger G (2008) Frequent biallelic inactivation and tran-scriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss. Int J Cancer 122:2503–2510

    PubMed  CAS  Google Scholar 

  • Rijpkema M, Schuuring J, van der Meulen Y, van der Graaf M, Bernsen H, Boerman R, van der Kogel A, Heerschap A (2003) Characterization of oli-godendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 16:12–18

    PubMed  CAS  Google Scholar 

  • Rodriguez FJ, Scheithauer B W, Jenkins R, Burger PC, Rudzinskiy P, Vlodavsky E, Schooley A, Landolfi J (2007) Gliosarcoma Arising in Oligo-dendroglial Tumors (“Oligosarcoma”): A Clinico-pathologic Study. Am J Surg Pathol 31:351–362

    PubMed  Google Scholar 

  • Sanson M, Leuraud P, Aguirre-Cruz L, He J, Marie Y, Cartalat-Carel S, Mokhtari K, Duffau H, Delattre JY, Hoang-Xuan K (2002) Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendroglio-mas. J Neurosurg 97:1397–1401

    PubMed  CAS  Google Scholar 

  • Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN (2001) PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159:359–367

    PubMed  CAS  Google Scholar 

  • Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, Louis DN (2002) Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade “oligoden-droglioma”. J Neuropathol Exp Neurol 61:58–63

    PubMed  Google Scholar 

  • Schiffer D, Bosone I, Dutto A, Di Vito N, Chio A (1999) The prognostic role of vessel productive changes and vessel density in oligodendrogli-oma. J Neurooncol 44:99–107

    PubMed  CAS  Google Scholar 

  • Schiffer D, Dutto A, Cavalla P, Bosone I, Chio A, Villani R, Bellotti C (1997) Prognostic factors in oligodendroglioma. Can J Neurol Sci 24:313–319

    PubMed  CAS  Google Scholar 

  • Sega S, Horvat A, Popovic M (2006) Anaplastic oli-godendroglioma and gliomatosis type 2 in inter-feron-beta treated multiple sclerosis patients. Report of two cases. Clin Neurol Neurosurg 108:259–265

    Google Scholar 

  • Shaw EG, Scheithauer B W, O'Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428–434

    PubMed  CAS  Google Scholar 

  • Shimizu KT, Tran LM, Mark RJ, Selch MT (1993) Management of oligodendrogliomas. Radiology 186:569–572

    PubMed  CAS  Google Scholar 

  • Shoshan Y, Nishiyama A, Chang A, Mork S, Barnett GH, Cowell JK, Trapp BD, Staugaitis SM (1999) Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci USA 96:10361–10366

    PubMed  CAS  Google Scholar 

  • Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer B W, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645

    PubMed  CAS  Google Scholar 

  • Smith SF, Simpson JM, Brewer JA, Sekhon LH, Biggs MT, Cook RJ, Little NS (2006) The presence of necrosis and/or microvascular proliferation does not influence survival of patients with ana-plastic oligodendroglial tumours: review of 98 patients. J Neurooncol 80(1):75–82

    PubMed  Google Scholar 

  • Soundar S, Danek BL, Colman RF (2000) IdentiWcation by mutagenesis of arginines in the substrate binding site of the porcine NADP-dependent isocitrate dehydrogenase. J Biol Chem 275:5606–5612

    PubMed  CAS  Google Scholar 

  • Stockhammer F, Thomale U, Plotkin M, Hartmann C, von Deimling A (2007) Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. J Neurosurg 106:633–637

    PubMed  CAS  Google Scholar 

  • Sun ZM, Genka S, Shitara N, Akanuma A, Takakura K (1988) Factors possibly influencing the prognosis of oligodendroglioma. Neurosurgery 22:886–891

    PubMed  CAS  Google Scholar 

  • Tanaka J, Hokama Y, Nakamura H (1988) Myelin basic protein as a possible marker for oligoden-droglioma. Acta Pathol Jpn 38:1297–1303

    PubMed  CAS  Google Scholar 

  • Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, Toedt G, Neben K, Hummerich L, von Deimling A, Reifenberger G, Lichter P (2006) Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer 119:792–800

    PubMed  CAS  Google Scholar 

  • Tews B, Roerig P, Hartmann C, Hahn M, Felsberg J, Blaschke B, Sabel M, Kunitz A, Toedt G, Neben K, Benner A, Deimling AV, Reifenberger G, Lichter P (2007) Hypermethylation and tran-scriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. Oncogene

    Google Scholar 

  • Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D (2003) Loss of hetero-zygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol 64:271–278

    PubMed  Google Scholar 

  • Tice H, Barnes PD, Goumnerova L, Scott RM, Tarbell NJ (1993) Pediatric and adolescent oli-godendrogliomas. AJNR Am J Neuroradiol 14:1293–1300

    PubMed  CAS  Google Scholar 

  • Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A, Kros JM, Stege EB, Enting RH, Allgeier A, van Heuvel I, van den Bent MJ (2004) Salvage PCV chemotherapy for temozolo-mide-resistant oligodendrogliomas. Neurology 63:904–906

    PubMed  CAS  Google Scholar 

  • Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, Fujimaki T, Hojo S, Kubo O, Ide T, Usui M, Ochiai C, Ito S, Takahashi H, Mukasa A, Asai A, Kirino T (2002) Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astro-cytic and oligodendroglial tumors. Clin Cancer Res 8:196–201

    PubMed  CAS  Google Scholar 

  • van den Bent MJ, Carpentier A F, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant procarbazine, lomustine, and vincris-tine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722

    PubMed  Google Scholar 

  • van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51:1140–1145

    Google Scholar 

  • Van Den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276–1284

    PubMed  Google Scholar 

  • van Dijk MC, Rombout PD, Boots-Sprenger SH, Straatman H, Bernsen MR, Ruiter DJ, Jeuken JW (2005) Multiplex ligation-dependent probe amplification for the detection of chromosomal gains and losses in formalin-fixed tissue. Diagn Mol Pathol 14:9–16

    PubMed  Google Scholar 

  • von Deimling A, Bender B, Jahnke R, Waha A, Kraus J, Albrecht S, Wellenreuther R, Fassbender F, Nagel J, Menon AG, Louis DN, Lenartz D, Schramm J, Wiestler OD (1994) Loci associated with malignant progression in astrocytomas: A candidate on chromosome 19q. Cancer Research 54:1397–1401

    Google Scholar 

  • von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, Jahnke R, Kaskel P, Duerr EM, Koopmann J, Maintz D, Steinbeck S, Wick W, Platten M, Muller DJ, Przkora R, Waha A, Blumcke B, Wellenreuther R, Meyer-Puttlitz B, Schmidt O, Mollenhauer J, Poustka A, Stangl A P, Lenartz D, von Ammon K (2000) Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 59:544–558

    Google Scholar 

  • von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR (1992) Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligoden-drogliomas, and mixed gliomas. Cancer Res 52:4277–4279

    Google Scholar 

  • Walker C, du Plessis DG, Joyce KA, Fildes D, Gee A, Haylock B, Husband D, Smith T, Broome J, Warnke PC (2005) Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol 57:855–865

    PubMed  CAS  Google Scholar 

  • Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H (2002) Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol (Berl) 103:267–275

    CAS  Google Scholar 

  • Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H (2001a) Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol (Berl) 101:185–189

    CAS  Google Scholar 

  • Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H (2001b) Concurrent inacti-vation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 60:1181–1189

    CAS  Google Scholar 

  • Watson MA, Perry A, Budhjara V, Hicks C, Shannon WD, Rich KM (2001) Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligoden-drogliomas. Cancer Res 61:1825–1829

    PubMed  CAS  Google Scholar 

  • Weber RG, Sabel M, Reifenberger J, Sommer C, Oberstrass J, Reifenberger G, Kiessling M, Cremer T (1996) Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene 13:983–994

    PubMed  CAS  Google Scholar 

  • Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach J, Ostertag C, Loeffler M, Pietsch T, von Deimling A (2007) Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13:6933–6937

    PubMed  CAS  Google Scholar 

  • Wharton SB, Hamilton FA, Chan WK, Chan KK, Anderson JR (1998) Proliferation and cell death in oligodendrogliomas. Neuropathol Appl Neurobiol 24:21–28

    PubMed  CAS  Google Scholar 

  • Wharton SB, Maltby E, Jellinek DA, Levy D, Atkey N, Hibberd S, Crimmins D, Stoeber K, Williams GH (2007) Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells. Acta Neuropathol (Berl) 113:119–127

    CAS  Google Scholar 

  • White ML, Zhang Y, Kirby P, Ryken TC (2005) Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 26:784–790

    PubMed  Google Scholar 

  • Winger MJ, Macdonald DR, Cairncross JG (1989) Supratentorial anaplastic gliomas in adults The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 71:487–493

    PubMed  CAS  Google Scholar 

  • Wolter M, Reifenberger J, Blaschke B, Ichimura K, Schmidt EE, Collins V P, Reifenberger G (2001) Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol 60:1170–1180

    PubMed  CAS  Google Scholar 

  • Wong AJ, Zoltick P W, Moscatello DK (1994) The molecular biology and molecular genetics of astrocytic neoplasms. Semin Oncol 21:139–148

    PubMed  CAS  Google Scholar 

  • Xu M, See SJ, Ng WH, Arul E, Back MF, Yeo TT, Lim CC (2005) Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 56:919–926; discussion 919–926

    PubMed  Google Scholar 

  • Yeh SA, Lee TC, Chen HJ, Lui CC, Sun LM, Wang CJ, Huang EY (2002) Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma. Int J Radiat Oncol Biol Phys 54:1405–1409

    PubMed  Google Scholar 

  • Yi L, Zhou ZH, Ping YF, Chen JH, Yao XH, Feng H, Lu JY, Wang JM, Bian XW (2007) Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocy-toma. Mod Pathol 20:1061–1068

    PubMed  CAS  Google Scholar 

  • Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC, Jr. (1999) NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 96:214–219

    PubMed  CAS  Google Scholar 

  • Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi J F, Betensky RA, Louis DN, Cairncross JG (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61:6713–6715

    PubMed  CAS  Google Scholar 

  • Zulch K (1986) Brain tumours. Their biologyand pathology. Springer, Berlin

    Google Scholar 

Download references

Author information

Authors
  1. Christian Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Andreas von Deimling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Hartmann .

Editor information

Editors and Affiliations

  1. Pathologisches Institut, UniversitäEtsklinikum Heidelberg, Abt. Neuropathologie, Germany

    Andreas von Deimling

  2. Deutsches Krebsforschungszentrum, Klinische Kooperationseinheit Neuropathologie, Im Neuenheimer Feld 220/221, Heidelberg, 69120, Germany

    Andreas von Deimling

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hartmann, C., von Deimling, A. (2009). Molecular Pathology of Oligodendroglial Tumors. In: von Deimling, A. (eds) Gliomas. Recent Results in Cancer Research, vol 171. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-31206-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-31206-2_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31205-5

  • Online ISBN: 978-3-540-31206-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation